



Mardi 21 mars 2023
Conférence de presse
La Sucrerie



BUSINESS PROPERTY DEVELOPMENT



BVI.EU – Davantage d'espace pour entreprendre



- **Pionnier des parcs d'entreprises PME | TPE**

Le fondateur originel

- **Parcs mixtes**

Combinaison de PME, bureaux, logistiques, immobilier, laboratoires, B2B showrooms, espaces co-working, etc.




- **Bâtiments semi-industriels et logistiques sur mesure**

Distribution, production, incubateur, centre de recherche et technologique, centre de triage, biotech, centre de formation, etc.

Le secteur des Biopharma à la rencontre des Deeptech

BELGIAN BIOPHARMA INDUSTRY FOOTPRINT



BELGIUM

- **12mn** people (10th)
- **30,000** sqm
- **42,000** biopharma workers
- **€500bn** GDP

R&D AND INNOVATION

INDUSTRIAL R&D INVESTMENT

Germany	7.8 bn €
Switzerland	7.4 bn €
U.K.	5.6 bn €
Belgium	5.0 bn €
France	4.5 bn €
Italy	1.6 bn €

Source: EFPIA 2022 report

- **6,300** researchers
- **€5bn** yearly R&D investment
- **500** new clinical trial authorizations yearly
- **€10bn** yearly venture capital, M&A, licensing deals

SELECTED PLAYERS

with Belgian
R&D footprint :



SELECTED DEALS

- Galapagos acquired CellPoint and AboundBio – 2022
- AbbVie acquired Syndesi Tx – 2022
- UCB acquired Handl Tx – 2022
- Thermo Fisher Scientific acquired Novasep-Henogen – 2021
- GSK entered R&D partnership with iTeos Tx – 2021
- Catalent acquired Masthercell & Delphi Genetics – 2020
- Sanofi acquired Ablynx Tx – 2018
- Astellas acquires Ogeda's phase 2 molecule – 2017

UNIVERSITIES & ACADEMIC HOSPITALS



10 UNIVERSITIES

with internationally renowned life sciences departments and research teams



70 hospitals among which
7 ACADEMIC HOSPITALS
with professional clinical trial centers employing 2800 physicians



2 BIOTECHNOLOGY

research centers




2 AI & NANOELECTRONICS


research centers



EROOM'S LAW IN THE BIOPHARMA R&D PROCESS




The inflation-adjusted **cost of developing a new drug roughly doubles every nine years.**



Source: Nature Reviews 2020 report | Ringel et al.

MOMENTUM FOR AI IN THE BIOPHARMA INDUSTRY



A new wave is coming:

- **300** biotech companies
- **150** molecules in the pipeline
- **15** in clinical development
- **\$8Bn** investment



Insilico
Medicine

insitro

Benevolent^{AI}

Qubit
pharmaceuticals

Exscientia


ON A MISSION TO ACCELERATE THE EMERGENCE OF THE NEXT NORMAL IN BIOTECH

By creating a space
where biotech meets
deeptech and digitech.


With the purpose of
pioneering AI-enabled
new ways of discovering,
developing and
commercializing drugs.



ATTRACTING INTERNATIONAL BIOTECH AND DEEPTECH COMPANIES



Europe represents 23% of global pharma market **and Belgium is one of the best bridgehead to the European market**



 **QUANTUM
BIOSPACE**
BY BVI.EU

PREMIUM LOCATION

In Wavre-Nord
prime
European
location



<30 MINUTE DRIVE

- Universities, Research Centers & Academic hospitals:** UCL (1) / KULeuven (2) / VUB (3) / ULB (4) / VIB (5) / WellBiotic (6) / imec (7) / ViTalent (8) / TRAIL (9) / CU Saint-Luc (10) / UZ Brussels (11) / UZ Leuven (12)
- Product and services companies:** GSK (1) / UCB (2) / IBA (3) / Novartis (4) / MSD (5) / Takeda (6) / Bayer (7) / BMS (8) / Boehringer Ingelheim (9) / Amgen (10) / J&J (11) / IQVIA (13) / Eli Lilly (12) / PPD (14) / Parexel (15) / Univercells (16) / Novadip (17)
- Institutions:** European Commission (1) / FAMHP (2) / EFPIA (3) / Essenscia (4) / Pharma.be (5) / AI4 Belgium (6)
- Venture Capital Funds:** Invest.BW (1) / FundPlus (2) / Newton Biocapital (3)

30-180 MINUTE DRIVE

- AptaSkil (1) / ViTalent (2) / EU Biotech School - starting in 2025 (2) / EMA - Amsterdam (3) / GENCI - Paris - High Performance Computing Center (4)





QUANTUM
BIOSPACE



BVIEU



- 17,5 Ha
- ▶ Pole R&D de 25.500 m²
- ▶ Pôle Entreprises : 32.500 m²
- ▶ Pôle Services de 5.500 m²
- ▶ **Total : 63.000 m² bâtiments**



963 places de parking



400 emplacements vélo




QUANTUM
BIOSPACE



BVI EU

Program



1. Research and Development:
25,500 sqm of R&D facilities for biotech
and deeptech activities

2. Manufacturing and commercialization

3. Community-supportive amenities



QUANTUM
BIOSPACE








QUANTUM
BIOSPACE
BY BVI.EU

Q6

BVI.EU


 QUANTUM
BIOSPACE



EMMA & JENNY
CONFERENCE CENTER

 **QUANTUM
BIOSPACE**
BY BVI.EU

Program



1. Research and Development

2. Manufacturing and commercialization: 32,500 sqm of industrial facilities with easy access for logistics operations, including a 5,000 sqm iconic office building.

3. Community-supportive amenities




QUANTUM
BIOSPACE

A10 BVI.EU





Program & timeline



1. Research and Development:

2. Manufacturing and commercialization:

3. Community-supportive amenities:
a 5,500 sqm area where your employees and guests can enjoy our fine restaurant, stay-over in our trendy boutique hotel or gain knowledge in our dedicated conference center.







Opening Phase “One”

Q3 2025



Geoffroy Dumonceau
Chief Development Officer
Geoffroy@bvi.eu
M. +32 471 20 20 13

Florence Bosco
Biotech Business Developer
Florence@bvi.eu
M. +32 496 54 05 65